PharVision Advisers’s Lifestance Health LFST Stock Holding History

PharVision Advisers’s Portfolio LFST Stock Details LFST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,251	Closed	-$83.9K	–	866
2025 Q3	$83.9K	Buy	+15,251	New	+$74.7K	0.05%	633

Other funds holding LFST

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Partners Boston, Massachusetts $670M AUM 6.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPIG

Silversmith Partners I GP Boston, Massachusetts $39.2M AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's LFST Position: Q4 2025 in Review

PharVision Advisers sold out of Lifestance Health (LFST) in Q4 2025, closing a stake of 15,251 shares — an estimated $83.9K sold.

PharVision Advisers first reported a position in LFST in Q3 2025 and held it in 1 quarter. The position peaked at $83.9K in Q3 2025. 204 funds tracked by Wall St. Rank hold LFST as of Q4 2025.

PharVision Advisers reported no remaining Lifestance Health position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 15,251 Lifestance Health shares in Q4 2025, an estimated $83.9K.
PharVision Advisers first reported a position in Lifestance Health in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Lifestance Health position peaked at $83.9K in Q3 2025.
204 funds tracked by Wall St. Rank held Lifestance Health as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.